```html

Inflammatory Colitis – A Comprehensive Medical Guide

Overview

Inflammatory colitis refers to a group of chronic disorders characterized by inflammation of the large intestine (colon). The most common forms are Ulcerative Colitis (UC) and Crohn’s disease involving the colon. While both are classified under inflammatory bowel disease (IBD), they differ in the pattern and depth of inflammation.

• Who it affects: Typically diagnosed in adolescents and young adults (15‑35 years), but it can appear at any age, including in children and seniors.
• Prevalence: In the United States, about 3 million people live with IBD; UC accounts for roughly 25‑30 % of cases (≈ 700,000 individuals)【1】. Worldwide prevalence ranges from 0.3 % in Asia to 0.5 %–0.6 % in North America and Europe【2】.
• Gender: Slightly more common in men with UC, whereas Crohn’s disease has a modest female predominance.

Symptoms

Symptoms can vary from mild to severe and may come and go in “flare‑ups.” A complete list includes:

• Diarrhea: Often watery, may contain mucus or blood.
• Rectal bleeding: Bright red blood on toilet paper or in stool.
• Abdominal pain & cramping: Typically in the lower left quadrant.
• Urgent need to defecate: May be accompanied by incomplete evacuation.
• Tenesmus: Persistent feeling that the bowels are not empty.
• Fever & chills: Common during active inflammation.
• Weight loss: Due to malabsorption and reduced appetite.
• Fatigue: Linked to chronic inflammation and anemia.
• Joint pain, eye inflammation, skin lesions: Extra‑intestinal manifestations in up to 25 % of patients.
• Growth delay in children: Result of poor nutrient absorption.

Causes and Risk Factors

Underlying Causes

The exact cause is unknown, but research points to a combination of:

1. Immune system dysfunction: The gut’s immune cells mistakenly attack the colon lining.
2. Genetic predisposition: Over 200 gene loci are associated with IBD; the strongest is NOD2/CARD15 for Crohn’s disease.
3. Environmental triggers: Smoking (protective for UC but risk‑enhancing for Crohn’s), diet high in processed foods, and antibiotic exposure early in life.
4. Microbiome alterations: Reduced diversity of beneficial bacteria can promote inflammation.

Risk Factors

• First‑degree relative with IBD (10‑20 % lifetime risk).
• European or Scandinavian ancestry.
• Living in urban, industrialized regions (higher incidence).
• History of gastrointestinal infections (e.g., Campylobacter, Salmonella).
• Use of non‑steroidal anti‑inflammatory drugs (NSAIDs) may exacerbate symptoms.

Diagnosis

Because symptoms overlap with infections, irritable bowel syndrome, and colorectal cancer, a systematic work‑up is essential.

Clinical Evaluation

• Medical history & physical exam: Document pattern of bowel movements, blood in stool, weight changes, and family history.
• Stool studies: Rule out infectious agents (culture, PCR for C. diff, ova & parasites).

Imaging & Endoscopic Tests

• Colonoscopy with biopsies: Gold standard. Allows direct visualization of ulcerations, pseudopolyps, and enables histologic confirmation.
• Flexible sigmoidoscopy: Useful for distal disease when full colonoscopy is not feasible.
• Magnetic resonance enterography (MRE) or CT enterography: Evaluate extent of disease, especially if Crohn’s involvement beyond the colon is suspected.
• Ultrasound (especially in Europe): Non‑invasive assessment of bowel wall thickness.

Laboratory Tests

• Complete blood count (CBC) – anemia, leukocytosis.
• C‑reactive protein (CRP) & erythrocyte sedimentation rate (ESR) – markers of inflammation.
• Fecal calprotectin – differentiates inflammatory from functional bowel disorders.
• Serologic markers (pANCA, ASCA) – adjunctive; not diagnostic alone.

Treatment Options

Treatment aims to induce remission, maintain it, and prevent complications. Choice depends on disease severity, extent, and patient preferences.

Medications

1. 5‑Aminosalicylic Acid (5‑ASA) agents: Mesalamine, sulfasalazine – first‑line for mild‑to‑moderate UC.
2. Corticosteroids: Prednisone, budesonide – used for moderate‑to‑severe flares; short‑term due to side‑effects.
3. Immunomodulators: Azathioprine, 6‑mercaptopurine, methotrexate – maintain remission, steroid‑sparing.
4. Biologic therapies:
   • Anti‑TNF agents (infliximab, adalimumab, certolizumab).
   • Anti‑integrin (vedolizumab) – gut‑specific.
   • IL‑12/23 inhibitor (ustekinumab).
   Effective for moderate‑to‑severe disease and those refractory to conventional drugs.
5. JAK inhibitors: Upadacitinib, tofacitinib – oral options for ulcerative colitis (FDA‑approved 2022).

Procedural & Surgical Options

• Endoscopic balloon dilation: For strictures in Crohn’s disease.
• Colectomy: Removal of the colon; curative for ulcerative colitis but not for Crohn’s disease. Options include total proctocolectomy with ileal pouch‑anal anastomosis (IPAA) or subtotal colectomy.
• Strictureplasty: Surgical widening of narrowed bowel segments (Crohn’s).

Lifestyle & Dietary Modifications

• Low‑residue (low‑fiber) diet during active flares to reduce stool bulk.
• Identify and avoid trigger foods – common culprits are spicy foods, caffeine, alcohol, and high‑lactose products.
• Maintain adequate hydration and electrolytes, especially with frequent diarrhea.
• Supplement iron, vitamin B12, calcium, and vitamin D when deficiencies are documented.
• Regular moderate exercise (e.g., walking, swimming) improves fatigue and mental health.

Living with Inflammatory Colitis

Daily Management Tips

1. Medication adherence: Use pill organizers, set alarms, and keep a medication log.
2. Symptom diary: Track stool frequency, consistency (Bristol Stool Chart), pain, and diet to identify patterns.
3. Stress management: Mindfulness, yoga, or cognitive‑behavioral therapy reduces flare‑triggering stress.
4. Regular follow‑up: Colonoscopy every 1‑3 years (per guidelines) to monitor inflammation and screen for dysplasia.
5. Vaccinations: Stay up‑to‑date on flu, COVID‑19, pneumococcal, and hepatitis B; discuss timing with your gastroenterologist, especially when on immunosuppressants.
6. Travel planning: Carry a “medical card” with diagnosis, current meds, and emergency contacts; pack extra medication and a copy of recent labs.

Psychosocial Support

Living with a chronic illness can affect mood and relationships. Consider:

• Support groups (local IBD societies, online forums).
• Professional counseling or psychotherapy.
• Open communication with family, employers, and educators about needed accommodations.

Prevention

Because the exact cause is not fully understood, “prevention” focuses on minimizing known risk enhancers and early detection of disease activity.

• Smoking cessation: Especially crucial for Crohn’s disease.
• Balanced diet rich in fruits, vegetables, and omega‑3 fatty acids: May favor a healthier gut microbiome.
• Avoid unnecessary antibiotics: Overuse can disrupt gut flora.
• Regular screening for at‑risk relatives: Colonoscopy or fecal calprotectin starting at age 10‑12 when a first‑degree relative has IBD.
• Vaccination: Prevent infections that could trigger flares (e.g., influenza, COVID‑19).

Complications

If inflammation is uncontrolled, a range of serious complications may arise:

• Colorectal cancer: Risk rises after 8‑10 years of extensive colitis; surveillance colonoscopy is essential.
• Primary sclerosing cholangitis (PSC): A liver disease seen in up to 5 % of UC patients.
• Severe bleeding or perforation: Can lead to peritonitis requiring emergent surgery.
• Strictures and fistulas: More common in Crohn’s disease; may need surgical intervention.
• Nutritional deficiencies: Iron, B12, folate, calcium, vitamin D.
• Osteoporosis: Chronic inflammation and steroid use decrease bone density.
• Psychiatric disorders: Anxiety, depression, and reduced quality of life are reported in up to 30 % of patients.

When to Seek Emergency Care

---

**References**

1. Mayo Clinic. Ulcerative colitis – Symptoms and causes. https://www.mayoclinic.org.
2. World Health Organization. Global IBD prevalence. WHO Fact Sheets, 2023. https://www.who.int.
3. Centers for Disease Control and Prevention. Crohn’s disease and ulcerative colitis. CDC, 2022. https://www.cdc.gov.
4. National Institute of Diabetes and Digestive and Kidney Diseases. Inflammatory bowel disease. NIH, 2024. https://www.niddk.nih.gov.
5. Cleveland Clinic. IBD treatment options. Cleveland Clinic, 2023. https://my.clevelandclinic.org.

```